-+ 0.00%
-+ 0.00%
-+ 0.00%
Zhitong Finance App News, Sinqi Pharmaceutical (300573.SZ) issued an announcement. Recently, the company received the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration regarding the SQ-25042 intraocular injection solution. SQ-25042 intraocular injection solution is a fusion protein independently developed by the company. It is a class 1 innovative drug for therapeutic biological products. It is clinically intended to treat neovascularization (wet) age-related macular degeneration (NaMD), diabetic macular edema (DME), and macular oedema secondary to retinal vein occlusion (RVO).
Share
Listen to the news
Zhitong Finance App News, Sinqi Pharmaceutical (300573.SZ) issued an announcement. Recently, the company received the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration regarding the SQ-25042 intraocular injection solution. SQ-25042 intraocular injection solution is a fusion protein independently developed by the company. It is a class 1 innovative drug for therapeutic biological products. It is clinically intended to treat neovascularization (wet) age-related macular degeneration (NaMD), diabetic macular edema (DME), and macular oedema secondary to retinal vein occlusion (RVO).
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending